CU23754B7 - Procedimiento para la preparación de 4-{4-[cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato. - Google Patents

Procedimiento para la preparación de 4-{4-[cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato.

Info

Publication number
CU23754B7
CU23754B7 CU20070069A CU20070069A CU23754B7 CU 23754 B7 CU23754 B7 CU 23754B7 CU 20070069 A CU20070069 A CU 20070069A CU 20070069 A CU20070069 A CU 20070069A CU 23754 B7 CU23754 B7 CU 23754B7
Authority
CU
Cuba
Prior art keywords
amino
formula
preparation
methylpiridine
phenoxi
Prior art date
Application number
CU20070069A
Other languages
English (en)
Other versions
CU20070069A7 (es
Inventor
Juergen Stiehl
Matthias Mueller-Gliemann
Mike Matthaeus
Oliver Kuhn
Jana Lenz
Mathias Berwe
Klaus Mohrs
Michael Loegers
Werner Heilmann
Reinhold Gehring
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU23754(B7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CU20070069A7 publication Critical patent/CU20070069A7/es
Publication of CU23754B7 publication Critical patent/CU23754B7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

El objeto de la presente invención pertenece al campo de la industria farmacéutica, específicamente relacionado con un procedimiento para la preparación de los compuestos de fórmula (I) y fórmula (II) útiles en el tratamiento del cáncer: (ESPACIO PARA FÓRMULAS) que comprende hacer reaccionar el compuesto de fórmula (V) con isocianato de 4-cloro-3-trifluorometilfenilo en un disolvente orgánico no clorado, inerte hacia isocianatos, a temperatura superior a 15sC proporcionando el compuesto de fórmula II y una segunda etapa, mezclando el compuesto de fórmula II con ácido p-toluenosulfónico.
CU20070069A 2004-09-29 2007-03-26 Procedimiento para la preparación de 4-{4-[cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato. CU23754B7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04023131 2004-09-29

Publications (2)

Publication Number Publication Date
CU20070069A7 CU20070069A7 (es) 2010-11-27
CU23754B7 true CU23754B7 (es) 2012-01-31

Family

ID=35457568

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20070069A CU23754B7 (es) 2004-09-29 2007-03-26 Procedimiento para la preparación de 4-{4-[cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato.

Country Status (34)

Country Link
US (1) US8124782B2 (es)
EP (1) EP1797037B1 (es)
JP (2) JP2008514657A (es)
KR (1) KR101263032B1 (es)
CN (1) CN101052619B (es)
AR (1) AR053973A1 (es)
AU (1) AU2005289099B2 (es)
BR (1) BRPI0515944B1 (es)
CA (1) CA2581835C (es)
CU (1) CU23754B7 (es)
CY (1) CY1116126T1 (es)
DK (1) DK1797037T3 (es)
DO (1) DOP2005000183A (es)
EC (1) ECSP077357A (es)
ES (1) ES2532377T3 (es)
GT (1) GT200500269A (es)
HN (1) HN2005000768A (es)
HR (1) HRP20150295T1 (es)
IL (1) IL182046A0 (es)
MA (1) MA28883B1 (es)
MY (1) MY149873A (es)
NO (1) NO339647B1 (es)
NZ (1) NZ554119A (es)
PE (5) PE20091585A1 (es)
PL (1) PL1797037T3 (es)
PT (1) PT1797037E (es)
SG (1) SG155997A1 (es)
SI (1) SI1797037T1 (es)
SV (1) SV2006002243A (es)
TW (1) TWI382973B (es)
UA (1) UA90691C2 (es)
UY (1) UY29143A1 (es)
WO (1) WO2006034796A1 (es)
ZA (1) ZA200702511B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041698A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2324825A1 (en) 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
DK1626714T3 (da) 2003-05-20 2007-10-15 Bayer Pharmaceuticals Corp Dirarylurinstoffer mod sygdomme medieret af PDGFR
CN1856469B (zh) 2003-07-23 2013-03-06 拜耳医药保健有限责任公司 用于治疗和预防疾病和疾病症状的氟代ω-羧芳基二苯基脲
KR20090018224A (ko) 2004-09-29 2009-02-19 바이엘 헬스케어 아게 열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
JP2008514657A (ja) 2004-09-29 2008-05-08 バイエル・ヘルスケア・アクチェンゲゼルシャフト ４−｛４−［（｛［４−クロロ−３−（トリフルオロメチル）フェニル］アミノ｝カルボニル）アミノ］フェノキシ｝−ｎ−メチルピリジン−２−カルボキサミドの製造方法
SI1868579T1 (sl) 2005-03-07 2011-02-28 Bayer Schering Pharma Ag Farmacevtski sestavek, ki obsega omega-karboksiarilno substituirano difenil sečnino, za zdravljenje raka
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008058644A1 (en) * 2006-11-14 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
KR101553211B1 (ko) 2007-09-10 2015-09-15 씨아이피엘에이 엘티디. Ｒａｆ 키나아제 저해제의 제조방법 및 상기 제조방법에 사용되는 중간체
WO2009054004A2 (en) * 2007-10-22 2009-04-30 Natco Pharma Limited Process for the preparation of sorafenib
EP2231612A1 (en) * 2008-01-17 2010-09-29 Sicor, Inc. Polymorph form iii of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof
US20090253913A1 (en) * 2008-03-06 2009-10-08 Pierluigi Rossetto Process for the preparation of sorafenib and salts thereof
CN103254126A (zh) * 2008-09-19 2013-08-21 苏州泽璟生物制药有限公司 氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
US8609854B2 (en) * 2009-09-24 2013-12-17 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
EP2480535A1 (en) 2009-09-24 2012-08-01 Ranbaxy Laboratories Limited Polymorphs of sorafenib acid addition salts
US8552197B2 (en) * 2009-11-12 2013-10-08 Ranbaxy Laboratories Limited Sorafenib ethylsulfonate salt, process for preparation and use
WO2011076711A2 (en) 2009-12-23 2011-06-30 Ratiopharm Gmbh Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide
AU2011210326B2 (en) 2010-01-29 2014-10-09 Sun Pharmaceutical Industries Limited Sorafenib dimethyl sulphoxide solvate
CN102190616B (zh) * 2010-03-18 2015-07-29 苏州泽璟生物制药有限公司 一种氘代的ω-二苯基脲的合成及生产的方法和工艺
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
CN102617458A (zh) * 2010-05-18 2012-08-01 张南 抗癌用化合物的制备方法
US20130183268A1 (en) 2010-07-19 2013-07-18 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
AP2013006834A0 (en) 2010-10-01 2013-04-30 Bayer Ip Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
WO2012071425A1 (en) 2010-11-22 2012-05-31 Teva Pharmaceutical Industries Ltd. Solid state forms of sorafenib besylate, and processes for preparations thereof
EP2559431A1 (en) 2011-08-17 2013-02-20 Ratiopharm GmbH Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
CN103664771B (zh) * 2012-09-19 2016-03-30 齐鲁制药有限公司 索拉非尼的晶型a及其制备方法
WO2014118807A1 (en) * 2013-02-04 2014-08-07 Intas Pharmaceuticals Limited A novel process for the preparation of sorafenib tosylate form iii
CN104710354A (zh) * 2013-12-13 2015-06-17 江苏豪森药业股份有限公司 高纯度索拉非尼的制备方法
CN104761492A (zh) * 2014-01-03 2015-07-08 正大天晴药业集团股份有限公司 对甲苯磺酸索拉非尼的晶型及其制备方法
CN104177292A (zh) * 2014-08-08 2014-12-03 亿腾药业（泰州）有限公司 一种工业化生产甲苯磺酸索拉非尼多晶型ⅰ的方法
CN105439947A (zh) * 2014-12-01 2016-03-30 石药集团中奇制药技术（石家庄）有限公司 一种甲苯磺酸索拉非尼新晶型及其制备方法
EP3109236B1 (en) 2015-06-23 2017-08-09 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Scalable process for the preparation of sorafenib tosylate ethanol solvate and sorafenib tosylate form iii
CN105181844A (zh) * 2015-09-11 2015-12-23 江苏嘉逸医药有限公司 一种高效液相色谱法测定甲苯磺酸索拉非尼含量和有关物质的方法
CN105585523A (zh) * 2015-12-29 2016-05-18 上海北卡医药技术有限公司 一种对甲苯磺酸索拉非尼的新晶型及其制备方法和用途
CN107840823B (zh) * 2016-09-20 2021-08-17 意大利合成制造有限公司 用于制备甲苯磺酸索拉非尼乙醇溶剂化物和iii型甲苯磺酸索拉非尼的可变规模的方法
CN107915676A (zh) * 2017-10-26 2018-04-17 魏海霞 索拉非尼的制备方法
CN109796400B (zh) * 2017-11-16 2022-07-29 四川科伦药物研究院有限公司 一种甲苯磺酸索拉菲尼晶型及其制备方法
CN113773249A (zh) * 2020-06-10 2021-12-10 杭州中美华东制药有限公司 索拉非尼游离碱晶型Form X及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU86960A1 (fr) * 1987-07-31 1989-03-08 Oreal Procede de preparation de piperidino-6 diamino-2,4 pyrimidine oxyde-3 et composes nouveaux
JPH02934A (ja) * 1988-05-27 1990-01-05 Konica Corp 非線形光学材料
JP2971291B2 (ja) * 1993-06-02 1999-11-02 田辺製薬株式会社 光学活性２−アミノ酪酸の製法
JP3866323B2 (ja) * 1996-03-27 2007-01-10 ポーラ化成工業株式会社 新規ｎ−ベンジルベンズアミド誘導体
JPH09316069A (ja) * 1996-03-28 1997-12-09 Ajinomoto Co Inc 新規キサントン誘導体
TNSN00010A1 (fr) * 1999-01-13 2002-05-30 Bayer Corp DIPHENYLUREE A SUBSTITUTION ω CARBOXYARYLE SERVANT D'INHIBUTEURS DE RAF KINASE.
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
GB2367816A (en) * 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
ES2393900T3 (es) * 2001-12-03 2012-12-28 Bayer Healthcare Llc Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DE10203086A1 (de) * 2002-01-28 2003-07-31 Bayer Ag 5-Ring Heterozyklen
EP2324825A1 (en) * 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
DE60336331D1 (de) * 2002-08-13 2011-04-21 Sandoz Ag Ein cefdinir-zwischenprodukt
DE60316590T2 (de) * 2002-10-21 2008-06-19 Kirin Beer K.K. N-(2-CHLOR-4-((6,7-DIMETHOXY-4-CHINOLYL)OXYÜPHENYLü-N'-(5-METHYL-3-ISOXAZOLYL)HARNSTOFFSALZIN KRISTALLINER FORM
DK1626714T3 (da) 2003-05-20 2007-10-15 Bayer Pharmaceuticals Corp Dirarylurinstoffer mod sygdomme medieret af PDGFR
JP2008514657A (ja) 2004-09-29 2008-05-08 バイエル・ヘルスケア・アクチェンゲゼルシャフト ４−｛４−［（｛［４−クロロ−３−（トリフルオロメチル）フェニル］アミノ｝カルボニル）アミノ］フェノキシ｝−ｎ−メチルピリジン−２−カルボキサミドの製造方法

Also Published As

Publication number Publication date
HK1113484A1 (en) 2008-10-03
EP1797037A1 (en) 2007-06-20
US20080262236A1 (en) 2008-10-23
PE20060825A1 (es) 2006-10-20
TW200626551A (en) 2006-08-01
SV2006002243A (es) 2006-10-13
NO339647B1 (no) 2017-01-16
JP5583190B2 (ja) 2014-09-03
ZA200702511B (en) 2008-07-30
IL182046A0 (en) 2007-07-24
GT200500269A (es) 2006-05-11
HN2005000768A (es) 2010-09-17
TWI382973B (zh) 2013-01-21
CU20070069A7 (es) 2010-11-27
UY29143A1 (es) 2006-04-28
AU2005289099B2 (en) 2012-07-19
AU2005289099A1 (en) 2006-04-06
PE20091586A1 (es) 2009-10-31
SI1797037T1 (sl) 2015-06-30
UA90691C2 (en) 2010-05-25
DOP2005000183A (es) 2006-03-31
PE20091584A1 (es) 2009-10-28
KR20070058676A (ko) 2007-06-08
NZ554119A (en) 2010-07-30
ES2532377T3 (es) 2015-03-26
MY149873A (en) 2013-10-31
JP2013067625A (ja) 2013-04-18
JP2008514657A (ja) 2008-05-08
DK1797037T3 (en) 2015-03-30
PE20091585A1 (es) 2009-10-31
CN101052619A (zh) 2007-10-10
MA28883B1 (fr) 2007-09-03
US8124782B2 (en) 2012-02-28
PL1797037T3 (pl) 2015-07-31
AR053973A1 (es) 2007-05-30
PT1797037E (pt) 2015-03-17
PE20091587A1 (es) 2009-11-05
CN101052619B (zh) 2012-02-22
KR101263032B1 (ko) 2013-05-09
EP1797037B1 (en) 2014-12-17
NO20072173L (no) 2007-06-14
ECSP077357A (es) 2007-04-26
CA2581835A1 (en) 2006-04-06
CA2581835C (en) 2012-12-18
SG155997A1 (en) 2009-10-29
BRPI0515944B1 (pt) 2021-11-09
CY1116126T1 (el) 2017-02-08
BRPI0515944A (pt) 2008-08-12
WO2006034796A1 (en) 2006-04-06
HRP20150295T1 (hr) 2015-05-22

Similar Documents

Publication Publication Date Title
CU23754B7 (es) Procedimiento para la preparación de 4-{4-[cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato.
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
BRPI0516911A (pt) método para a preparação de um composto e composto de anilina
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
EA200971104A1 (ru) Производные бензимидазола
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
ECSP088368A (es) Derivados de 3-alquil-5-(4-alquil-5-oxo-tetrahidrofuran-2-il)-pirrolidin-2-ona como intermediarios en la síntesis de inhibidores de renina
ATE442349T1 (de) Diacylglycerol-acyltransferase-hemmer
MX2007012212A (es) 1h-pirazol 4-carboxilamidas, su preparacion y su uso como 11-beta-hidroxiesteroide deshidrogenasa.
PE20061422A1 (es) Tigeciclina y metodos para preparar 9-nitrominociclina
BRPI0610644B8 (pt) composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
BRPI0712889A8 (pt) composto, processo para a preparação de um composto, composto intermediário, e, composição farmacêutica.
UY29613A1 (es) Compuestos quimicos vi
BRPI0415203A (pt) pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios
Rakesh et al. Synthesis and SAR studies of potent H+/K+-ATPase and anti-inflammatory activities of symmetrical and unsymmetrical urea analogues
UY29607A1 (es) Compuestos quimicos
JO2734B1 (en) Organic compounds
MX2011008677A (es) Derivados de pirazolopirimidina triciclicos.
BRPI0808570B8 (pt) processo para a preparação de inibidores de glyt-1
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
CR20210173A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
BRPI0702817A (pt) compostos de naftaleno, processo para sua preparação e composições farmacêuticas que contêm esses compostos
Saleh et al. New AZO Compounds Derivatives Based on 4-chloro-2-((5-formyl-2-hydroxy-3-methoxyphenyl) diazenyl) benzenesulfonamide: Preparation, diagnostic, Spectroscopic, Antioxidant and Antimicrobial efficiency
BRPI0702769A (pt) compostos de naftaleno, processo para sua preparação e composições farmacêuticas contendo os mesmos

Legal Events

Date Code Title Description
FG Grant of patent